Candriam SCA’s Cardiff Oncology CRDF Stock Holding History

Candriam SCA’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-344,437	Closed	-$968K	–	702
2025 Q4	$968K	Buy	+344,437	New	+$800K	﹤0.01%	590

Other funds holding CRDF

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

Candriam SCA's CRDF Position: Q1 2026 in Review

Candriam SCA sold out of Cardiff Oncology (CRDF) in Q1 2026, closing a stake of 344,437 shares — an estimated $968K sold.

Candriam SCA first reported a position in CRDF in Q4 2025 and held it in 1 quarter. The position peaked at $968K in Q4 2025. 117 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

Candriam SCA reported no remaining Cardiff Oncology position as of Q1 2026 after selling out during the quarter.
Candriam SCA sold 344,437 Cardiff Oncology shares in Q1 2026, an estimated $968K.
Candriam SCA first reported a position in Cardiff Oncology in Q4 2025 and held it in 1 quarter.
Candriam SCA's Cardiff Oncology position peaked at $968K in Q4 2025.
117 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.